Abstract
DNA vaccines promote immune system activation in small animals and exhibit certain advantages when compared to conventional recombinant protein vaccines. However in clinical trials DNA vaccines are less effective in inducing potent immune responses due to the low delivery efficiency and expression of antigens. Currently, various delivery devices such as gene-guns, bioinjectors and electroporation systems are being used in order to increase the potency of DNA vaccines. However, the optimal delivery parameters are required and must be carefully set to obtain the highest levels of gene expression and strong immune responses in humans. The focus of this study was to optimize electroporation settings (voltage, pulse length, pulse intervals, and number of pulses), as well as the route of administration (intradermal vs. intramuscular) and dosage of the DNA epitope vaccine, AV-1959D, delivered by the BTX AgilePulseTM system. As a result, we have chosen the optimal settings for electroporation delivery using different routes of immunization with this vaccine, generating (i) robust antibody production to the B cell epitope (a small peptide, derived from β-amyloid), and (ii) strong cellular immune responses to Th epitopes (a small synthetic peptide and eleven peptides from various pathogens) incorporated into DNA vaccine platform.
Keywords: AV-1959D vaccine, electroporation device, immune responses, intradermal delivery, intramuscular delivery, optimization of BTX AgilePulseTM system, plasmid immunizations.
Current Gene Therapy
Title:BTX AgilePulseTM System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Volume: 14 Issue: 3
Author(s): Hayk Davtyan, Armine Hovakimyan, Karen Zagorski, Arpine Davtyan, Irina Petrushina, David Agdashian, Vidya Murthy, David H. Cribbs, Michael G. Agadjanyan and Anahit Ghochikyan
Affiliation:
Keywords: AV-1959D vaccine, electroporation device, immune responses, intradermal delivery, intramuscular delivery, optimization of BTX AgilePulseTM system, plasmid immunizations.
Abstract: DNA vaccines promote immune system activation in small animals and exhibit certain advantages when compared to conventional recombinant protein vaccines. However in clinical trials DNA vaccines are less effective in inducing potent immune responses due to the low delivery efficiency and expression of antigens. Currently, various delivery devices such as gene-guns, bioinjectors and electroporation systems are being used in order to increase the potency of DNA vaccines. However, the optimal delivery parameters are required and must be carefully set to obtain the highest levels of gene expression and strong immune responses in humans. The focus of this study was to optimize electroporation settings (voltage, pulse length, pulse intervals, and number of pulses), as well as the route of administration (intradermal vs. intramuscular) and dosage of the DNA epitope vaccine, AV-1959D, delivered by the BTX AgilePulseTM system. As a result, we have chosen the optimal settings for electroporation delivery using different routes of immunization with this vaccine, generating (i) robust antibody production to the B cell epitope (a small peptide, derived from β-amyloid), and (ii) strong cellular immune responses to Th epitopes (a small synthetic peptide and eleven peptides from various pathogens) incorporated into DNA vaccine platform.
Export Options
About this article
Cite this article as:
Davtyan Hayk, Hovakimyan Armine, Zagorski Karen, Davtyan Arpine, Petrushina Irina, Agdashian David, Murthy Vidya, Cribbs H. David, Agadjanyan G. Michael and Ghochikyan Anahit, BTX AgilePulseTM System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine, Current Gene Therapy 2014; 14 (3) . https://dx.doi.org/10.2174/1566523214666140522121427
DOI https://dx.doi.org/10.2174/1566523214666140522121427 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cetuximab: Its Use in Combination with Radiation Therapy and Chemotherapy in the Multimodality Treatment of Head and Neck Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Application of Poly-Epsilon-Caprolactone and its Derivative Copolymers for Controlled Release of Anti-Tumor Drugs
Current Cancer Drug Targets Extra-telomeric Functions of Human Telomerase: Cancer, Mitochondria and Oxidative Stress
Current Pharmaceutical Design Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer
Current Pharmaceutical Design Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics New Treatment Concepts In Diffuse Large B-Cell Lymphomas (DLBL): Chemotherapy and Biological Therapy
Reviews on Recent Clinical Trials MRI of the Small and Large Bowel
Current Medical Imaging Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration
Current Drug Targets Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Estrogen Receptors: Molecular Interactions, Virtual Screening and Future Prospects
Current Topics in Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
Current Medicinal Chemistry Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?
Reviews on Recent Clinical Trials